GOSS Key Statistics, Chart & Performance
The current stock price of GOSS is 3.21 USD. In the past month the price decreased by -3.89%. In the past year, price increased by 214.71%.
GOSS Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.43 | 407.98B | ||
| AMGN | AMGEN INC | 15.07 | 177.50B | ||
| GILD | GILEAD SCIENCES INC | 15.25 | 154.97B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.49 | 116.66B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.34 | 82.03B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 782 | 52.69B | ||
| INSM | INSMED INC | N/A | 37.61B | ||
| NTRA | NATERA INC | N/A | 31.92B | ||
| BIIB | BIOGEN INC | 10.56 | 25.94B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.06 | 21.65B | ||
| INCY | INCYTE CORP | 15.47 | 19.49B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.34B |
Related stock screener links
About GOSS
Company Profile
Gossamer Bio, Inc. engages in discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company is headquartered in San Diego, California and currently employs 144 full-time employees. The company went IPO on 2019-02-08. Seralutinib, also known as GB002, is an investigational inhaled, small-molecule, platelet-derived growth factor receptor (PDGFR), colony-stimulating factor 1 receptor (CSF1R), and c-KIT inhibitor, being evaluated in a Phase III clinical trial for the treatment of PAH. Seralutinib is designed to target the mechanisms that underlie pulmonary hypertension and to be delivered to the site of disease, via dry powder inhaler. Seralutinib is being evaluated in a Phase III clinical trial for the treatment of pulmonary arterial hypertension (PAH). Inhaled seralutinib, which is designed to act on both isoforms of the PDGFR, α and β, as well as the CSF1R and c-KIT pathways.
Company Info
GOSSAMER BIO INC
3115 Merryfield Row, Suite 120
San Diego CALIFORNIA 92121 US
CEO: Faheem Hasnain
Employees: 144
Phone: 18586841300
GOSSAMER BIO INC / GOSS FAQ
What does GOSS do?
Gossamer Bio, Inc. engages in discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company is headquartered in San Diego, California and currently employs 144 full-time employees. The company went IPO on 2019-02-08. Seralutinib, also known as GB002, is an investigational inhaled, small-molecule, platelet-derived growth factor receptor (PDGFR), colony-stimulating factor 1 receptor (CSF1R), and c-KIT inhibitor, being evaluated in a Phase III clinical trial for the treatment of PAH. Seralutinib is designed to target the mechanisms that underlie pulmonary hypertension and to be delivered to the site of disease, via dry powder inhaler. Seralutinib is being evaluated in a Phase III clinical trial for the treatment of pulmonary arterial hypertension (PAH). Inhaled seralutinib, which is designed to act on both isoforms of the PDGFR, α and β, as well as the CSF1R and c-KIT pathways.
Can you provide the latest stock price for GOSSAMER BIO INC?
The current stock price of GOSS is 3.21 USD. The price decreased by -0.62% in the last trading session.
Does GOSS stock pay dividends?
GOSS does not pay a dividend.
What is the ChartMill rating of GOSSAMER BIO INC stock?
GOSS has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the sector and industry classification for GOSSAMER BIO INC?
GOSSAMER BIO INC (GOSS) operates in the Health Care sector and the Biotechnology industry.
What is the employee count for GOSS stock?
GOSSAMER BIO INC (GOSS) currently has 144 employees.
What is the market capitalization of GOSS stock?
GOSSAMER BIO INC (GOSS) has a market capitalization of 742.99M USD. This makes GOSS a Small Cap stock.
GOSS Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to GOSS. When comparing the yearly performance of all stocks, GOSS is one of the better performing stocks in the market, outperforming 98.44% of all stocks.
GOSS Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to GOSS. Both the profitability and financial health of GOSS have multiple concerns.
GOSS Financial Highlights
Over the last trailing twelve months GOSS reported a non-GAAP Earnings per Share(EPS) of -0.69. The EPS decreased by -115.63% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -74.77% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
GOSS Forecast & Estimates
15 analysts have analysed GOSS and the average price target is 9.62 USD. This implies a price increase of 199.6% is expected in the next year compared to the current price of 3.21.
For the next year, analysts expect an EPS growth of -181.48% and a revenue growth -62.36% for GOSS